High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C.
Int J Mol Sci. 2019 Feb 22;20(4):952. doi: 10.3390/ijms20040952.
Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y, Tan Y, Zhou D, Bai Y, Cao T, Zhong C, Huang W, Ou Y, Guo L, Liu Q, Yin D, Chen L, Luo X, Sun D, Sheng X.
Front Immunol. 2022 Jul 22;13:923194. doi: 10.3389/fimmu.2022.923194. eCollection 2022.
High-grade serous carcinoma of tubo-ovarian origin: recent developments.
Singh N, McCluggage WG, Gilks CB.
Histopathology. 2017 Sep;71(3):339-356. doi: 10.1111/his.13248. Epub 2017 Jul 18.
Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes.
Casey L, Singh N.
Surg Pathol Clin. 2019 Jun;12(2):515-528. doi: 10.1016/j.path.2019.01.007.
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Grisham RN, Slomovitz BM, Andrews N, Banerjee S, Brown J, Carey MS, Chui H, Coleman RL, Fader AN, Gaillard S, Gourley C, Sood AK, Monk BJ, Moore KN, Ray-Coquard I, Shih IM, Westin SN, Wong KK, Gershenson DM.
Int J Gynecol Cancer. 2023 Sep 4;33(9):1331-1344. doi: 10.1136/ijgc-2023-004610.
Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
D'Angelo E, Espinosa I, Felicioni L, Buttitta F, Prat J.
Hum Pathol. 2023 Nov;141:15-21. doi: 10.1016/j.humpath.2023.08.010. Epub 2023 Sep 9.
Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N.
J Clin Oncol. 2015 Aug 1;33(22):2457-63. doi: 10.1200/JCO.2014.60.5212. Epub 2015 Jun 29.
The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions.
Cheng Z, Ennis DP, Lu B, Mirza HB, Sokota C, Kaur B, Singh N, Le Saux O, Russo G, Giannone G, Tookman LA, Krell J, Barnes C, McDermott J, McNeish IA.
J Pathol. 2024 Sep;264(1):42-54. doi: 10.1002/path.6322. Epub 2024 Jul 2.
Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.
Voutsadakis IA.
Int J Gynecol Cancer. 2020 Oct;30(10):1619-1626. doi: 10.1136/ijgc-2019-000832. Epub 2019 Nov 27.
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Smith P, Bradley T, Gavarró LM, Goranova T, Ennis DP, Mirza HB, De Silva D, Piskorz AM, Sauer CM, Al-Khalidi S, Funingana IG, Reinius MAV, Giannone G, Lewsley LA, Stobo J, McQueen J, Bryson G, Eldridge M; BriTROC Investigators; Macintyre G, Markowetz F, Brenton JD, McNeish IA.
Nat Commun. 2023 Jul 20;14(1):4387. doi: 10.1038/s41467-023-39867-7.
